Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins Plasmapheresis and Rituximab in Lung Transplantation

  • STATUS
    Recruiting
  • End date
    Dec 5, 2022
  • participants needed
    70
  • sponsor
    Hannover Medical School
Updated on 5 September 2021
rituximab

Summary

Single-arm, prospective observational study

Description

This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.

Details
Condition Lung transplant, Organ Transplantation, Organ Transplant - Pediatric, Organ Transplant, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, lung transplantation, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
Treatment blood samples
Clinical Study IdentifierNCT03798860
SponsorHannover Medical School
Last Modified on5 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

all patients after lung transplantation with detection of donor-specific antibodies

Exclusion Criteria

none
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note